Last reviewed · How we verify
oxaliplatin plus capecitabine
Oxaliplatin and capecitabine work together as a chemotherapy combination where oxaliplatin cross-links DNA to prevent replication while capecitabine is converted to fluorouracil to inhibit thymidylate synthase and disrupt nucleotide synthesis.
Oxaliplatin and capecitabine work together as a chemotherapy combination where oxaliplatin cross-links DNA to prevent replication while capecitabine is converted to fluorouracil to inhibit thymidylate synthase and disrupt nucleotide synthesis. Used for Metastatic colorectal cancer, Gastric cancer, Pancreatic cancer.
At a glance
| Generic name | oxaliplatin plus capecitabine |
|---|---|
| Also known as | Two medicine combined, Oxaliplatin plus capecitabine other names:XELOX. |
| Sponsor | LiNing |
| Drug class | Platinum-based chemotherapy combination |
| Target | DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Oxaliplatin is a third-generation platinum compound that forms DNA adducts, triggering apoptosis in cancer cells. Capecitabine is an oral prodrug of 5-fluorouracil that inhibits thymidylate synthase, blocking dTMP synthesis and causing DNA strand breaks. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
- Gastric cancer
- Pancreatic cancer
Common side effects
- Neuropathy (peripheral sensory)
- Nausea and vomiting
- Diarrhea
- Neutropenia
- Anemia
- Hand-foot syndrome
- Fatigue
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (PHASE3)
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (PHASE2)
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (PHASE2)
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) (PHASE1, PHASE2)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxaliplatin plus capecitabine CI brief — competitive landscape report
- oxaliplatin plus capecitabine updates RSS · CI watch RSS
- LiNing portfolio CI